Mark Gorovoy, MD
Ophthalmology · Fort Myers, FLNPI 1043213051
Payments from drug & device makers
Across 197 payments — averaging $179.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kowa Research Institute, Inc.$19K
- Glaukos Corporation$8K
- Alcon$2K
- Aerie Pharmaceuticals, Inc.$750
- Kowa Pharmaceuticals America, Inc.$672
- Regeneron Healthcare Solutions, Inc.$614
- plus $4K from 26 others
Across 1 payment — averaging $4138.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$4K
What the payments were for
- Consulting fees$1502%
- Speaking & faculty fees$6728%
- Travel & lodging$1,89523%
- Food & beverage$5,43366%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kowa Research Institute, Inc. | 6 | $19,477 |
| Glaukos Corporation | 11 | $7,979 |
| Alcon | 22 | $2,057 |
| Aerie Pharmaceuticals, Inc. | 3 | $750 |
| Kowa Pharmaceuticals America, Inc. | 1 | $672 |
| Regeneron Healthcare Solutions, Inc. | 19 | $614 |
| AbbVie(2 entities) | 27 | $603 |
| Johnson & Johnson Surgical Vision, Inc. | 21 | $498 |
| Bausch & Lomb Americas Inc. | 15 | $396 |
| Dompe US, Inc. | 11 | $395 |
| Astellas Pharma US Inc | 6 | $375 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $289 |
| Sun Pharmaceutical Industries Inc. | 6 | $246 |
| Ivantis, Inc | 2 | $202 |
| Apellis Pharmaceuticals, Inc. | 1 | $125 |
| Harrow Eye, LLC | 5 | $122 |
| Oyster Point Pharma, Inc. | 6 | $107 |
| Ocular Therapeutix, Inc. | 4 | $83 |
| Novartis | 4 | $77 |
| Amgen(2 entities) | 4 | $64 |
| Rayner Intraocular Lenses Limited | 2 | $59 |
| Genentech USA, Inc. | 2 | $39 |
| Kala Pharmaceuticals, Inc. | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Tarsus Pharmaceuticals, Inc. | 1 | $27 |
| NEW World Medical,inc. | 1 | $22 |
| Iridex Corporation | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Carl Zeiss Meditec USA, Inc. | 1 | $17 |
| Sight Sciences, Inc. | 1 | $16 |
| Merz North America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$1,460
- iStent infinite Trabecular Micro-Bypass System Model iS3$187
- Hydrus$150
- Oxervate$129
- Syfovre$125
- MIEBO$125
- XIIDRA$125
- Izervay$123
- Rocklatan$120
- Rhopressa$120
- Tecnis Simplicity$117
- ENVISTA TORIC$114
How this compares
$35,437 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 20 | $676,428 |
| RestasisCyclosporine | 95 | $110,178 |
| Prednisolone Acetate | 1,662 | $73,133 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $16,711 |
| VyzultaLatanoprostene Bunod | 23 | $16,120 |
| Loteprednol Etabonate | 89 | $15,790 |
| MieboPerfluorohexyloctane/Pf | 21 | $15,592 |
| XiidraLifitegrast | 13 | $12,648 |
| LumiganBimatoprost | 27 | $12,500 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 662 | $11,363 |
| Fluorometholone | 136 | $11,192 |
| Ketorolac Tromethamine | 512 | $11,078 |
| MoxifloxacinMoxifloxacin Hcl | 335 | $9,440 |
| RhopressaNetarsudil Mesylate | 14 | $8,944 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 31 | $8,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $395 | $676,42820 claims |
| AbbVieRestasis, Combigan, Lumigan | $603 | $139,389156 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo, Xiidra, Zirgan | $396 | $51,98072 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa | $289 | $21,670102 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $750 | $8,94414 claims |
| AlconSimbrinza | $2,057 | $8,50131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Fort Myers
- Stephen SmithFort Myers$591K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.